These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34272910)

  • 1. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, for lower urinary tract dysfunction in mice with spinal cord injury.
    Shimizu N; Gotoh D; Nishimoto M; Hashimoto M; Saito T; Fujita K; Hirayama A; Yoshimura N; Uemura H
    Int J Urol; 2021 Oct; 28(10):1068-1072. PubMed ID: 34272910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new β3-adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury.
    Gotoh D; Shimizu N; Wada N; Kadekawa K; Saito T; Mizoguchi S; Morizawa Y; Hori S; Miyake M; Torimoto K; de Groat WC; Fujimoto K; Yoshimura N
    Neurourol Urodyn; 2020 Nov; 39(8):2120-2127. PubMed ID: 32816344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of p38 MAP kinase signaling pathways in storage and voiding dysfunction in mice with spinal cord injury.
    Shimizu N; Wada N; Shimizu T; Suzuki T; Kurobe M; Kanai AJ; de Groat WC; Hashimoto M; Hirayama A; Uemura H; Yoshimura N
    Neurourol Urodyn; 2020 Jan; 39(1):108-115. PubMed ID: 31579964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of a soluble guanylate cyclase activator, BAY 60-2770, on lower urinary tract dysfunction in mice with spinal cord injury.
    Gotoh D; Saito T; Karnup S; Morizawa Y; Hori S; Nakai Y; Miyake M; Torimoto K; Fujimoto K; Yoshimura N
    Am J Physiol Renal Physiol; 2022 Oct; 323(4):F447-F454. PubMed ID: 35952343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of intravenous and intravesical application of vibegron, a β
    Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urodynamic effect of vibegron on neurogenic lower urinary tract dysfunction in individuals with spinal cord injury: A retrospective study.
    Matsuda K; Teruya K; Uemura O
    Spinal Cord; 2022 Aug; 60(8):716-721. PubMed ID: 35177800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.
    Kato T; Mizuno K; Nishio H; Yasui T; Hayashi Y
    J Med Case Rep; 2021 Feb; 15(1):86. PubMed ID: 33602290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of neutralization of nerve growth factor (NGF) on bladder and urethral dysfunction in mice with spinal cord injury.
    Wada N; Shimizu T; Shimizu N; de Groat WC; Kanai AJ; Tyagi P; Kakizaki H; Yoshimura N
    Neurourol Urodyn; 2018 Aug; 37(6):1889-1896. PubMed ID: 29516546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vibegron inhibits enhanced spontaneous contractions induced by anoxia/reoxygenation in isolated whole bladder from rats.
    Ikeda M; Nakada A; Abukawa H; Yamazaki T; Maruyama I
    Eur J Pharmacol; 2022 Jul; 926():175017. PubMed ID: 35588870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats.
    Yamazaki T; Maruyama I
    Eur J Pharmacol; 2019 Dec; 864():172727. PubMed ID: 31600494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
    Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Video-urodynamic effects of vibegron, a new selective β3-adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida.
    Aoki K; Momose H; Gotoh D; Morizawa Y; Hori S; Nakai Y; Miyake M; Anai S; Torimoto K; Tanaka N; Yoneda T; Matsumoto Y; Fujimoto K
    Int J Urol; 2022 Jan; 29(1):76-81. PubMed ID: 34608669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of lower urinary tract dysfunction by a monoacylglycerol lipase inhibitor in mice with spinal cord injury.
    Cho KJ; Hashimoto M; Karnup S; Matsuoka K; Kamijo T; Kim JC; Koh JS; Yoshimura N
    Neurourol Urodyn; 2024 Jun; 43(5):1207-1216. PubMed ID: 38533637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vibegron, a novel β
    Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
    Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of vibegron, a β
    Aizawa N; Fujita T
    Eur J Pharmacol; 2022 Oct; 933():175272. PubMed ID: 36108733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
    Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
    J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifibrosis treatment by inhibition of VEGF, FGF, and PDGF receptors improves bladder wall remodeling and detrusor overactivity in association with modulation of C-fiber afferent activity in mice with spinal cord injury.
    Kwon J; Lee EJ; Cho HJ; Jang JA; Han MS; Kwak E; Kim H; An J; Park D; Han S; Shimizu N; Suzuki T; Takaoka EI; Yoshimura N
    Neurourol Urodyn; 2021 Aug; 40(6):1460-1469. PubMed ID: 34015154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent progression of neurogenic lower urinary tract dysfunction after spinal cord injury in the mouse model.
    Saito T; Gotoh D; Wada N; Tyagi P; Minagawa T; Ogawa T; Ishizuka O; Yoshimura N
    Am J Physiol Renal Physiol; 2021 Jul; 321(1):F26-F32. PubMed ID: 33969698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.